Pharmaceutical industry in India

Downstream Processing Market Size Worth $69.6 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 2, 2021
Healthcare in India, Pharmaceutical industry in India, Telecommunications, Cisco Systems, Companies, Computer networking

SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global downstream processing market size is expected to reachUSD 69.6 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global downstream processing market size is expected to reachUSD 69.6 billion by 2028, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at aCAGR of 15.9% from 2021 to 2028.
  • A rise in applications of downstream processing for the manufacture of biopharmaceuticals is expected to bring growth opportunities to the market.
  • Grand View Research has segmented the global downstream processing market on the basis of product, technique, application, and region:
    Downstream Processing Product Outlook (Revenue, USD Million, 2017 - 2028)

Downstream Processing Market Size Worth $69.6 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 2, 2021
Healthcare in India, Pharmaceutical industry in India, Telecommunications, Cisco Systems, Companies, Computer networking

SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global downstream processing market size is expected to reachUSD 69.6 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global downstream processing market size is expected to reachUSD 69.6 billion by 2028, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at aCAGR of 15.9% from 2021 to 2028.
  • A rise in applications of downstream processing for the manufacture of biopharmaceuticals is expected to bring growth opportunities to the market.
  • Grand View Research has segmented the global downstream processing market on the basis of product, technique, application, and region:
    Downstream Processing Product Outlook (Revenue, USD Million, 2017 - 2028)

TABMELT® Granted Patent Rights in Russia, Expanding Vivera Global Licensing

Retrieved on: 
Thursday, February 25, 2021
Health sciences, Health care, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Patent, Pharmaceutical industry in India, Pharmaceutical industry

NEWPORT BEACH, Calif., Feb. 25, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, Inc., is pleased to announce the expansion of its exclusive global licensing of the novel TABMELT platform to Russia.

Key Points: 
  • NEWPORT BEACH, Calif., Feb. 25, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, Inc., is pleased to announce the expansion of its exclusive global licensing of the novel TABMELT platform to Russia.
  • The latest TABMELT patent approval comes as the Company begins to expand its pharmaceutical offerings into neuroscience, and joins Canada, the United Kingdom, and Australia as countries that have granted patent rights to the TABMELT sublingual technology.
  • "With the finalization and granting of the long-awaited Russian patent, TABMELT has an even stronger international presence," states Paul Edalat, CEO of Vivera Pharmaceuticals.
  • "With Vivera's exclusive global license of the TABMELT technology for use in pharmaceuticals, we are able to develop better medications for patients at home and abroad.

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

Retrieved on: 
Monday, February 22, 2021
Health care, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Pharmaceutical industry in India

SAN FRANCISCO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market.

Key Points: 
  • SAN FRANCISCO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market.
  • The global veterinary oncology market size was estimated at USD 199.9 million in 2019 and is anticipated to witness a Compound Annual Growth Rate (CAGR) of 10.7% over the next decade.
  • ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.
  • For additional information, please contact the Oncology Pharma at:

iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021

Retrieved on: 
Tuesday, February 9, 2021
Natural sciences, Branches of biology, Life sciences, Biotechnology, Contract manufacturing organization, Pharmaceutical industry in India, Pharming, Glycosylation

BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results after market close on Tuesday, February 16, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Key Points: 
  • BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results after market close on Tuesday, February 16, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
  • The live and archived webcast may be accessed on the Companys website at www.ibioinc.com under News and Events in the Investors section.
  • iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others.
  • The Companys subsidiary, iBio CDMO LLC, providesFastPharmingContract Development and Manufacturing Services along with the GlycaneeringDevelopment Services for the control and tailoring of N-glycosylation.

Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Monday, February 8, 2021
Life sciences, Articles, Health, Tonix Pharmaceuticals, Biopharmaceutical, Pharmaceutical industry in China, Pharmaceutical industry in India, Prospectus

The gross proceeds of the offering will be approximately $70 million before deducting fees and other estimated offering expenses.

Key Points: 
  • The gross proceeds of the offering will be approximately $70 million before deducting fees and other estimated offering expenses.
  • The closing of the registered direct offering is expected to take place on or about February 9, 2021, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement relating to the shares of common stock will be filed by Tonix with the SEC.
  • About Tonix Pharmaceuticals Holding Corp.
    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

DGAP-News: Wacker Chemie AG: WACKER Strengthens Biologics Business by Acquiring US-Based Plasmid DNA Manufacturer Genopis

Retrieved on: 
Wednesday, February 3, 2021
Wacker, Health care, Health, Pharmaceutical industry in India, Contract manufacturing organization, Vaccine, SynCo Bio Partners

WACKER will continue Genopis' existing customer relationships as a contract manufacturer (CDMO) for plasmid DNA (pDNA).

Key Points: 
  • WACKER will continue Genopis' existing customer relationships as a contract manufacturer (CDMO) for plasmid DNA (pDNA).
  • "Genopis' expertise in plasmid DNA technology expands our portfolio as a pharmaceutical-sector contract manufacturer.
  • "Acquiring Genopis is an ideal way to complement our existing activities as a contract manufacturer of biopharmaceuticals and vaccines," explains Susanne Leonhartsberger, president of the WACKER BIOSOLUTIONS division.
  • Wacker Biotech GmbH and Wacker Biotech B.V. are wholly owned subsidiaries of Munich-based Wacker Chemie AG (WCH888).

Global Enzymes Market Outlook to 2027 - Featuring Sanofi, Roche Holding and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 2, 2021
Health, Biotechnology, Healthcare in India, Pharmaceutical industry in India

The "Enzymes - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enzymes - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • According to the report, the Global Enzymes Market accounted for $10.19 billion in 2019 and is expected to reach $19.87 billion by 2027, growing at a CAGR of 8.7% during the forecast period.
  • High demand for effective enzymes based pharmaceuticals, rising demand from various industries and advancements in R&D activities for technical enzymes are some of the factors propelling the growth of the market.
  • However, stringent regulatory framework and handling & safety issues of enzymes are hampering the growth of the market.

Adare Pharma Solutions Opens New Small-Scale Laboratory to Offer Faster and More Efficient Development Capabilities to Clients.

Retrieved on: 
Tuesday, January 26, 2021
Health care, Health, Aptalis, Contract manufacturing organization, Pharmaceutical industry in China, Pharmaceutical industry in India

LAWRENCEVILLE, N.J., Jan. 26, 2021 /PRNewswire/ -- Adare Pharma Solutions, ("Adare") a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise, is proud to announce the opening of a new small-scale development laboratory in Vandalia, Ohio.

Key Points: 
  • LAWRENCEVILLE, N.J., Jan. 26, 2021 /PRNewswire/ -- Adare Pharma Solutions, ("Adare") a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise, is proud to announce the opening of a new small-scale development laboratory in Vandalia, Ohio.
  • Adare built the non-GMP laboratory to encompass two rooms that are physically separated from the FDA, GMP certified pilot and production areas.
  • This new laboratory spacebrings customizable, flexible systems that will expedite formulation and process development services.
  • Adare Pharma Solutions, formerly Adare Pharmaceuticals, is a leading specialty contract development and manufacturing organization (CDMO) and a leading global provider of advanced pharmaceutical technologies, development, and manufacturing.

Adare Pharma Solutions Opens New Small-Scale Laboratory to Offer Faster and More Efficient Development Capabilities to Clients.

Retrieved on: 
Tuesday, January 26, 2021
Health care, Health, Aptalis, Contract manufacturing organization, Pharmaceutical industry in China, Pharmaceutical industry in India

LAWRENCEVILLE, N.J., Jan. 26, 2021 /PRNewswire/ -- Adare Pharma Solutions, ("Adare") a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise, is proud to announce the opening of a new small-scale development laboratory in Vandalia, Ohio.

Key Points: 
  • LAWRENCEVILLE, N.J., Jan. 26, 2021 /PRNewswire/ -- Adare Pharma Solutions, ("Adare") a global technology-driven CDMO providing turnkey product development through commercial manufacturing expertise, is proud to announce the opening of a new small-scale development laboratory in Vandalia, Ohio.
  • Adare built the non-GMP laboratory to encompass two rooms that are physically separated from the FDA, GMP certified pilot and production areas.
  • This new laboratory spacebrings customizable, flexible systems that will expedite formulation and process development services.
  • Adare Pharma Solutions, formerly Adare Pharmaceuticals, is a leading specialty contract development and manufacturing organization (CDMO) and a leading global provider of advanced pharmaceutical technologies, development, and manufacturing.